Prothena Corporation plc

Prothena Announces Addition of Seasoned Executive to Board of Directors

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson’s Disease

Prothena to Present at JMP Securities Life Science Conference 2015 on June 23

Prothena’s NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association

Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association

Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases